

# **Anaesthetic Management of Diabetic Child**

*Essay*

Submitted for Partial Fulfillment of the Master Degree  
in Anaesthesia

*By*

**Mohammed Sayed Hussain Sayed**

M.B.B.CH

Cairo University

*Under Supervision of*

**Prof. Dr. Alaa Eid Mohamed Hassan**

Professor of Anesthesiology and Intensive Care  
Faculty of Medicine, Ain Shams University

**Prof. Dr. Hazem Mohamed Abdel-Rahman Fawzy**

Professor of Anesthesiology and Intensive Care  
Faculty of Medicine, Ain Shams University

**Dr. Dalia Mahmoud Ahmed ElFawzy**

Lecturer of Anaesthesia and Intensive Care  
Faculty of Medicine, Ain Shams University

*Faculty of Medicine  
Ain Shams University*

**2016**



وَأَنْزَلَ اللَّهُ عَلَيْكَ  
الْكِتَابَ وَالْحِكْمَةَ  
وَعَلَّمَكَ مَا لَمْ تَكُنْ  
تَعْلَمُ وَكَانَ فَضْلُ  
اللَّهِ عَلَيْكَ عَظِيمًا

صدق الله العظيم □

□ سورة النساء الآية (١١٣)



## Acknowledgments

*First and foremost, I feel always indebted to Allah the Most Beneficent and Merciful.*

*I wish to express my deepest gratitude and thanks to **Prof. Dr. Alaa Eid Mohamed Hassan**, Professor of Anesthesiology and Intensive Care, Faculty of Medicine, Ain Shams University, for his constructive criticism, unlimited help and giving me the privilege to work under his supervision.*

*My most sincere gratitude is also extended to **Prof. Dr. Hazem Mohamed Abdel-Rahman Fawzy**, Professor of Anesthesiology and Intensive Care, Faculty of Medicine, Ain Shams University, for his enthusiastic help, continuous supervision, guidance and support throughout this work.*

*Words fail to express my appreciation to **Dr. Dalia Mahmoud Ahmed El-Fawy**, Lecturer of Anaesthesia and Intensive Care, Faculty of Medicine, Ain Shams University, for the time and efforts she has devoted to accomplish this work.*

*Last but not least, I can't forget to thank all members of my Family for pushing me forward in every step in the journey of my life.*

*Candidate*

 **Mohammed Sayed Hussain Sayed**

## **List of Contents**

<i><b>Subject</b></i>	<i><b>Page No.</b></i>
<b>List of Abbreviations .....</b>	<b>i</b>
<b>List of Tables.....</b>	<b>iii</b>
<b>List of Figures .....</b>	<b>iv</b>
<b>Introduction .....</b>	<b>1</b>
<b>Aim of the Study .....</b>	<b>3</b>
<b>Chapter (1): Pathophysiology of Diabetes Mellitus.....</b>	<b>4</b>
<b>Chapter (2): Management of Diabetes Mellitus in Children.....</b>	<b>28</b>
<b>Chapter (3): Anaesthetic Management of Diabetic Child.....</b>	<b>74</b>
<b>Summary .....</b>	<b>101</b>
<b>References .....</b>	<b>103</b>
<b>Arabic Summary .....</b>	<b>—</b>

---

## List of Abbreviations

<i>Abbr.</i>	<i>Full-term</i>
<b>ACR</b>	: Albumin/creatinine ratio
<b>ADA</b>	: American Diabetes Association
<b>BG</b>	: Blood glucose
<b>BOHB</b>	: Blood glucose and measure blood $\beta$ -hydroxybutyrate
<b>cIMT</b>	: Carotid intima-media thickness
<b>CKD</b>	: Chronic kidney disease
<b>CSII</b>	: Continuous subcutaneous insulin infusion
<b>CVD</b>	: Cardiovascular disease
<b>DHC</b>	: Diabetes healthcare
<b>DKA</b>	: Diabetic ketoacidosis
<b>DN</b>	: Diabetic neuropathy
<b>ECG</b>	: Electrocardiogram
<b>eGFR</b>	: Estimated GFR
<b>GA</b>	: General anesthetic
<b>GAD</b>	: Glutamic acid decarboxylase
<b>I-A2</b>	: Insulinoma-associated antigen 2
<b>IAA</b>	: Insulin auto antibodies
<b>ICA</b>	: Islet cell antibodies
<b>ICU</b>	: Intensive care unit
<b>IV</b>	: Intravenous

## **List of Abbreviations (Cont.)**

<i>Abbr.</i>	<i>Full-term</i>
<b>IFG</b>	: Impaired fasting glycaemia
<b>IGT</b>	: Impaired glucose tolerance
<b>IMCL</b>	: Intramyocellular lipid content
<b>IV</b>	: Intravenous
<b>LDL-C</b>	: Low-density lipoprotein cholesterol
<b>MODY</b>	: Maturity onset diabetes of the young
<b>NPH</b>	: Neutral protamine Hagedorn
<b>NPO</b>	: Nil per os
<b>OGTT</b>	: Oral glucose tolerance test
<b>OHAs</b>	: Oral hypoglycaemic agents
<b>PG</b>	: Plasma glucose; SC, subcutaneous.
<b>PPI</b>	: Preproinsulin
<b>T1D</b>	: Type 1 diabetes
<b>TCRs</b>	: T cell antigen receptors
<b>TDD</b>	: Total daily dose
<b>TPN</b>	: Total parenteral nutrition
<b>Treg</b>	: T regulatory
<b>VDD</b>	: Vitamin D deficiency
<b>ZnT8</b>	: Zinc transporter

## **List of Tables**

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Table (1):</b>	Etiologic classification of diabetes mellitus.....	5
<b>Table (2):</b>	Criteria for the diagnosis of diabetes mellitus .....	10
<b>Table (3):</b>	Types of insulin and time of action:.....	34
<b>Table (4):</b>	Examples of carbohydrate for treatment of mild-to-moderate hypoglycemia .....	42
<b>Table (5):</b>	Clinical features in evaluation of a child with diabetic ketoacidosis (DKA).....	47
<b>Table (6):</b>	Monitoring of clinical signs and biochemical investigations and their frequency .....	50
<b>Table (7):</b>	Screening for diabetes complications, dyslipidemia and hypertension in children with type 1 diabetes.....	65
<b>Table (8):</b>	Recommendations for screening for comorbid conditions in children with type 1 diabetes .....	69
<b>Table (9):</b>	Infusion guide for surgical procedures.....	90

## List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Figure (1):</b>	A Model for the Pathogenesis of Type 1 Diabetes Based on Genetic Etiological Studies in Humans Shown are genes. ....	14
<b>Figure (2):</b>	Currently Mapped Type 1 Non-HLA Diabetes Loci and Candidate Causal Genes.....	15
<b>Figure (3):</b>	Liver fat content and impairment of insulin sensitivity and $\beta$ -cell function in obese children and adolescents .....	27
<b>Figure (4):</b>	Relation between level and time of rapid acting insulin .....	32
<b>Figure (5):</b>	Relation between level and time of short acting insulin .....	33
<b>Figure (6):</b>	Relation between level and time of intermediate acting insulin .....	33
<b>Figure (7):</b>	Relation between level and time of long acting insulin .....	34
<b>Figure (8):</b>	Insulin injections and vials.....	35
<b>Figure (9):</b>	Insulin pens.....	35
<b>Figure (10):</b>	Insulin pump .....	36
<b>Figure (11):</b>	Insulin inhaler.....	37
<b>Figure (12):</b>	Insulin jet injectors .....	38
<b>Figure (13):</b>	Pathophysiology of DKA .....	43
<b>Figure (14):</b>	Immediate assessment and management of diabetic ketoacidosis (DKA) in children.....	62

## **List of Figures (Cont.)**

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Figure (15):</b>	Diabetes mellitus perioperative management clinical practice guideline .....	84
<b>Figure (16):</b>	Intraoperative management .....	95

## Introduction

**D**iabetes mellitus is a group of metabolic diseases characterised by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. If ketones are present in blood or urine, treatment is urgent, because ketoacidosis can evolve rapidly (*Craig et al., 2009*).

Type 1 diabetes results from the autoimmune destruction of insulin-producing  $\beta$  cells in the pancreas. Genetic and, as yet undefined, environmental factors act together to precipitate the disease. The excess mortality associated with the complications of type 1 diabetes and the increasing incidence of childhood type 1 diabetes emphasize the importance of therapeutic strategies to prevent this chronic disorder (*Kathleen, 2006*). Type 2 diabetes in youth was almost unheard of only two decades ago. However, tracking the recent dramatic rise in childhood obesity, type 2 diabetes has become increasingly prevalent (*Gemmill et al., 2011*).

The incidence of both type 1 and type 2 diabetes mellitus in children is increasing worldwide. The use of insulin pumps and various multicomponent insulin regimens has increased the complexity of perioperative management of children with diabetes. Anesthesiologists must carefully consider the pathophysiology of the disease, as well as each child's specific diabetes treatment regimen, glycemic control, intended surgery, and anticipated postoperative course, when devising an

appropriate perioperative management plan. Standardized algorithms for perioperative diabetes management improve care without significantly increasing costs (*Krane et al., 2013*).

When children with diabetes require surgery or other procedures requiring sedation or anaesthesia, optimal management should maintain adequate hydration and near to normal glycemia, while minimising the risk of hypoglycemia. The stress of surgery may cause acute hyperglycemia, which increases the risk of postoperative infection (*Betts et al., 2009*). The management of the pediatric patient before, during and after surgery or diagnosis is aimed at maintaining a normal glucose level; i.e. plasma sugar between 100 y 200 mg/dL. The goal is to keep the patient within this range to reduce the risk of osmotic diuresis, dehydration, hydroelectrolytic imbalance, metabolic acidosis, infection and hypoglycemia. The diabetic child scheduled for minor surgical interventions can be admitted on the same day of surgery, while those scheduled for major surgical procedures should be admitted one day before surgery (*Ana et al., 2011*).

Once the child is able to resume oral nutrition, resume the child's usual diabetes treatment regimen. Give short- or rapid-acting insulin (based on the child's usual insulin: carbohydrate ratio and correction factor), if needed, to reduce hyperglycemia or to match food intake (*Erinn et al., 2014*).

## **Aim of the Study**

**T**he aim of this study is to provide clear and standardised guidelines for all staff caring for paediatric patients with type 1 and 2 diabetes requiring a general anaesthetic or sedation for surgery.

## Chapter (1): Pathophysiology of Diabetes Mellitus

### **Definition:**

Diabetes mellitus is a general term for heterogeneous disturbances of metabolism for which the main finding is chronic hyperglycaemia. The cause is either impaired insulin secretion or impaired insulin action or both. The definition includes the following criteria:

- HbA1c  $\geq 6.5\%$  ( $\geq 48\text{mmol/mol}$ )
- Random plasma glucose  $\geq 200\text{mg/dl}$  ( $\geq 11.1\text{mmol/l}$ )
- Fasting plasma glucose  $\geq 126\text{mg/dl}$  ( $\geq 7.0\text{mmol/dl}$ )
- OGTT 2-hour glucose in venous plasma  $\geq 200\text{mg/dl}$  ( $\geq 11.1\text{mmol/l}$ )

These guidelines have been recommending the use of HbA1c for diagnosing diabetes since 2010 (*Kerner et al., 2014*).

## **Classification**

**Table (1):** Etiologic classification of diabetes mellitus  
(*Drouin et al., 2013*)

<input type="checkbox"/> Type 1 diabetes ( $\beta$ -cell destruction, usually leading to absolute insulin deficiency) <ul style="list-style-type: none"><li>A. Immune mediated</li><li>B. Idiopathic</li></ul>
<input type="checkbox"/> Type 2 diabetes (may range from predominantly insulin resistance with relative insulin deficiency to a predominantly secretory defect with insulin resistance)
<input type="checkbox"/> Other specific types <ul style="list-style-type: none"><li>A. Genetic defects of <math>\beta</math>-cell function<ol style="list-style-type: none"><li>1. Chromosome 12, HNF-1<math>\alpha</math> (MODY3)</li><li>2. Chromosome 7, glucokinase (MODY2)</li><li>3. Chromosome 20, HNF-4<math>\alpha</math> (MODY1)</li><li>4. Chromosome 13, insulin promoter factor-1 (IPF-1; MODY4)</li><li>5. Chromosome 17, HNF-1<math>\beta</math> (MODY5)</li><li>6. Chromosome 2, <i>NeuroD1</i> (MODY6)</li><li>7. Mitochondrial DNA</li><li>8. Others</li></ol></li><li>B. Genetic defects in insulin action<ol style="list-style-type: none"><li>1. Type A insulin resistance</li><li>2. Leprechaunism</li><li>3. Rabson-Mendenhall syndrome</li><li>4. Lipotrophic diabetes</li><li>5. Others</li></ol></li><li>C. Diseases of the exocrine pancreas<ol style="list-style-type: none"><li>1. Pancreatitis</li><li>2. Trauma/pancreatectomy</li><li>3. Neoplasia</li><li>4. Cystic fibrosis</li><li>5. Hemochromatosis</li><li>6. Fibrocalculous pancreatopathy</li><li>7. Others</li></ol></li><li>D. Endocrinopathies<ol style="list-style-type: none"><li>1. Acromegaly</li><li>2. Cushing's syndrome</li><li>3. Glucagonoma</li></ol></li></ul>

4. Pheochromocytoma
5. Hyperthyroidism
6. Somatostatinoma
7. Aldosteronoma
8. Others
- E. Drug or chemical induced
  1. Vacor
  2. Pentamidine
  3. Nicotinic acid
  4. Glucocorticoids
  5. Thyroid hormone
  6. Diazoxide
  7.  $\beta$ -adrenergic agonists
  8. Thiazides
  9. Dilantin
  10.  $\gamma$ -Interferon
  11. Others
- F. Infections
  1. Congenital rubella
  2. Cytomegalovirus
  3. Others
- G. Uncommon forms of immune-mediated diabetes
  1. “Stiff-man” syndrome
  2. Anti-insulin receptor antibodies
  3. Others
- H. Other genetic syndromes sometimes associated with diabetes
  1. Down syndrome
  2. Klinefelter syndrome
  3. Turner syndrome
  4. Wolfram syndrome
  5. Friedreich ataxia
  6. Huntington chorea
  7. Laurence-Moon-Biedl syndrome
  8. Myotonic dystrophy
  9. Porphyria
  10. Prader-Willi syndrome
  11. Others

☐ Gestational diabetes mellitus